- Home
- DTF vs KZIA Comparison
DTF vs KZIA Comparison
Compare DTF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | KZIA |
|---|---|---|
| Founded | 1991 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | DTF | KZIA |
|---|---|---|
| Price | $11.39 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 21.1K | ★ 255.5K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.29 | $2.86 |
| 52 Week High | $11.19 | $17.40 |
Technical Indicators
Market Signals| Indicator | DTF | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 47.35 |
| Support Level | $11.39 | $6.85 |
| Resistance Level | $11.50 | $7.69 |
| Average True Range (ATR) | 0.06 | 0.70 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 53.91 | 82.85 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.